Vanda Pharmaceuticals: Strategic Investments and Market Potential in Focus - Experts See 218% Price Potential

Quarterly Results Under the Sign of Investments Vanda Pharmaceuticals (VNDA) looks back on a phase of strategic market expansion in the first quarter of 2026, which is clearly reflected in the current financial figures. The company recorded total revenue of $51.7 million, representing an increase of three percent compared to the same period last year. At the same time, the company reported a net loss of $0.82 per share, compared to a loss of $0.50 in the first quarter of 2025. From the company's perspective, this increased loss is a calculated...